MA32838B1 - Procede de modulation de l'activite antagoniste d'un anticorps monoclonal - Google Patents

Procede de modulation de l'activite antagoniste d'un anticorps monoclonal

Info

Publication number
MA32838B1
MA32838B1 MA33899A MA33899A MA32838B1 MA 32838 B1 MA32838 B1 MA 32838B1 MA 33899 A MA33899 A MA 33899A MA 33899 A MA33899 A MA 33899A MA 32838 B1 MA32838 B1 MA 32838B1
Authority
MA
Morocco
Prior art keywords
antibody
antibody activity
modifying
monoclonal antibodies
target molecule
Prior art date
Application number
MA33899A
Other languages
Arabic (ar)
English (en)
Inventor
Liliane Goetsch
Thierry Wurch
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2008/055664 external-priority patent/WO2010064090A1/fr
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA32838B1 publication Critical patent/MA32838B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention a trait au domaine de l'ingénierie des anticorps et plus particulièrement à un procédé de criblage d'anticorps et/ou de modulation de l'activité agoniste ou antagoniste d'anticorps, et plus particulièrement encore à un procédé améliorant l'activité antagoniste d'un anticorps monoclonal dirigé contre une molécule cible spécifique ou contre l'un de ses fragments fonctionnels divalents ou l'un de ses dérivés, ledit anticorps étant capable d'inhiber une ou plusieurs des activités biologiques de ladite molécule cible, et ledit procédé comportant une étape de reconfiguration de la région charnière, consistant à modifier la séquence d'acides aminés de ladite région par suppression, addition ou substitution d'au moins un acide aminé. L'invention porte également sur des polypeptides utilisables dans ladite méthode de modulation, et sur les anticorps ainsi obtenus.
MA33899A 2008-12-02 2011-05-31 Procede de modulation de l'activite antagoniste d'un anticorps monoclonal MA32838B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2008/055664 WO2010064090A1 (fr) 2008-12-02 2008-12-02 Procédé de modulation de l'activité antagoniste d'un anticorps monoclonal
US18440609P 2009-06-05 2009-06-05
PCT/EP2009/066205 WO2010063746A1 (fr) 2008-12-02 2009-12-02 Procédé de modulation de l'activité antagoniste d'un anticorps monoclonal

Publications (1)

Publication Number Publication Date
MA32838B1 true MA32838B1 (fr) 2011-11-01

Family

ID=41668304

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33899A MA32838B1 (fr) 2008-12-02 2011-05-31 Procede de modulation de l'activite antagoniste d'un anticorps monoclonal

Country Status (21)

Country Link
US (3) US9676839B2 (fr)
EP (2) EP3048113A1 (fr)
JP (1) JP5832899B2 (fr)
KR (2) KR20110091519A (fr)
CN (2) CN105820241A (fr)
AR (1) AR074438A1 (fr)
AU (1) AU2009324145B2 (fr)
BR (1) BRPI0923228B1 (fr)
CA (1) CA2744065C (fr)
DK (1) DK2370464T3 (fr)
ES (1) ES2600254T3 (fr)
GE (1) GEP20135931B (fr)
IL (1) IL213272A (fr)
MA (1) MA32838B1 (fr)
MX (1) MX2011005569A (fr)
NZ (1) NZ592830A (fr)
SA (1) SA109300723B1 (fr)
TN (1) TN2011000253A1 (fr)
TW (1) TWI631341B (fr)
WO (1) WO2010063746A1 (fr)
ZA (1) ZA201103831B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
EP2009101B1 (fr) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Procede de modification d'anticorps pour purifier un anticorps bispecifique
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP3415529B1 (fr) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Région constante d'anticorps modifié
WO2010107110A1 (fr) 2009-03-19 2010-09-23 中外製薬株式会社 Variant d'une région constante d'anticorps
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
WO2011110642A2 (fr) 2010-03-10 2011-09-15 Genmab A/S Anticorps monoclonaux contre c-met
EP2708556B1 (fr) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Composition pharmaceutique à utiliser dans une thérapie combinée pour la prévention ou le traitement des maladies induites par c-met ou le facteur d'angiogénèse
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CN107172880B (zh) * 2014-03-24 2021-09-28 癌症研究技术有限公司 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
WO2016161010A2 (fr) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Régions constantes de chaînes lourdes présentant une liaison réduite aux récepteurs fc gamma
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
KR102777500B1 (ko) 2015-09-23 2025-03-11 리제너론 파아마슈티컬스, 인크. 최적화된 항-cd3 이중특이적 항체 및 이의 용도
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
PL3532497T3 (pl) 2016-10-26 2024-11-04 The Board Of Trustees Of The Leland Stanford Junior University Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji
US12516088B2 (en) * 2018-06-15 2026-01-06 The Regents Of The University Of California Fusion fragment chimeric antigen receptors and uses thereof
PT3844189T (pt) 2018-08-31 2025-01-29 Regeneron Pharma Estratégia de dosagem que mitiga a síndrome de libertação de citocinas para anticorpos bisepecíficos contra cd3/c20
WO2022104692A1 (fr) * 2020-11-20 2022-05-27 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Anticorps modifié, conjugué anticorps-médicament et son utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315457D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
KR101223373B1 (ko) 2003-12-25 2013-01-16 교와 핫꼬 기린 가부시키가이샤 항 ｃｄ４０ 항체의 변이체
US8008443B2 (en) * 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
DK1915398T3 (en) * 2005-07-18 2016-07-04 Amgen Inc Humane anti-B7RP1 neutraliserende antistoffer
WO2007016285A2 (fr) * 2005-07-28 2007-02-08 Novartis Ag Anticorps monoclonal specifique de m-csf et ses utilisations
TW200808347A (en) * 2006-03-23 2008-02-16 Kirin Brewery Agonistic antibody directed against human thrombopoietin receptor
CL2007000851A1 (es) * 2006-03-30 2008-03-14 Novartis Ag Anticuerpo anti receptor del factor de crecimiento del hepatocito (c-met); adn que codifican cadenas livianas y pesadas del anticuerpo; composicion farmaceutica y kit que comprenden dicho anticuerpo; metodo para tratar trastorno relacionado con c-met
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody

Also Published As

Publication number Publication date
ZA201103831B (en) 2012-01-25
JP2012510281A (ja) 2012-05-10
DK2370464T3 (en) 2016-11-21
WO2010063746A1 (fr) 2010-06-10
CN102232086B (zh) 2016-03-16
JP5832899B2 (ja) 2015-12-16
IL213272A0 (en) 2011-07-31
TN2011000253A1 (en) 2012-12-17
GEP20135931B (en) 2013-10-10
ES2600254T3 (es) 2017-02-08
US20110263830A1 (en) 2011-10-27
CN102232086A (zh) 2011-11-02
HK1163704A1 (zh) 2012-09-14
KR20170021378A (ko) 2017-02-27
BRPI0923228A2 (pt) 2021-02-09
AU2009324145B2 (en) 2015-01-22
NZ592830A (en) 2013-03-28
BRPI0923228B1 (pt) 2022-03-03
AR074438A1 (es) 2011-01-19
CA2744065C (fr) 2017-09-12
TWI631341B (zh) 2018-08-01
SA109300723B1 (ar) 2014-10-27
EP3048113A1 (fr) 2016-07-27
KR101971806B1 (ko) 2019-08-27
AU2009324145A1 (en) 2010-06-10
US20130109839A1 (en) 2013-05-02
TW201024734A (en) 2010-07-01
MX2011005569A (es) 2011-06-16
IL213272A (en) 2017-08-31
KR20110091519A (ko) 2011-08-11
EP2370464A1 (fr) 2011-10-05
CN105820241A (zh) 2016-08-03
EP2370464B1 (fr) 2016-07-27
US9676839B2 (en) 2017-06-13
CA2744065A1 (fr) 2010-06-10
RU2011124749A (ru) 2013-01-10
US20150239958A1 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
TN2011000253A1 (en) Process for the modulation of the antagonistic activity of a monoclonal antibody
MY157173A (en) Modified humanised anti-interleukin-18
WO2010091182A3 (fr) Procédés pour cribler des agents candidats pour la modulation de la prorénine et de la rénine, tests de détection de la prorénine, et anticorps qu'ils emploient
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
ATE530195T1 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
CR20120587A (es) Moléculas de unión al antígeno que fijan egfr, vectores que las codifican y uso de las mismas
DE602006013029D1 (de) Anti-egfr-antikörper
MX2018005512A (es) Agentes de union de esclerostina.
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
EA201592042A1 (ru) Композиции антител против cgrp и их применение
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
MX2018013008A (es) Anticuerpos st-2 humanos solubles y ensayos.
UA97946C2 (ru) Моноклональное антитело, специфически связывающееся с внеклеточным доменом ilt7 человека
MX2018008680A (es) Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).
DE602005022830D1 (de) Weniger immunogene bindungsmoleküle
WO2009088924A3 (fr) Procédés et matériaux pour une amélioration d'affinité ciblée
WO2009126934A3 (fr) Détection et traitement du cancer du pancréas, des ovaires et d'autres cancers
NZ593964A (en) Human anti-alpha-synuclein autoantibodies
GB201005064D0 (en) Biological products
MX2010006767A (es) Anticuerpos de virus de hepatitis c.
WO2019060750A3 (fr) Compositions d'anticorps a33 et leurs méthodes d'utilisation en radioimmunothérapie
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper